P1722: CHANGES IN ACUTE HEPATIC PORPHYRIA HEALTH IMPACTS SINCE INITIAL DIAGNOSIS: RESULTS FROM THE PORPHYRIA WORLDWIDE PATIENT EXPERIENCE RESEARCH (POWER) STUDY

• D. Nance,
• D. Lyon,
• S. Hegarty,
• R. Falchetto,
• J. Barman-Aksözen,
• T. Mnif,
• S. Meninger,
• S. Lombardelli,
• A. Dickey

Affiliations

D. Nance

1 Banner Health, Gilbert

D. Lyon

2 American Porphyria Foundation, Bethesda, United States of America

S. Hegarty

3 Global Porphyria Advocacy Coalition, Durham City, United Kingdom

R. Falchetto

4 Swiss Society for Porphyria

J. Barman-Aksözen

4 Swiss Society for Porphyria

T. Mnif

6 Cerner Enviza, Paris, France

S. Meninger

7 Alnylam Pharmaceuticals, Cambridge, United States of America

S. Lombardelli

8 Alnylam Pharmaceuticals, Maidenhead, United Kingdom

A. Dickey

9 Massachusetts General Hospital, Boston, United States of America